Interview with Patrick Terry, Acting CEO of the Grand Therapeutics Foundation, and Christopher Austin, M.D., Director of the NIH Chemical Genomics Center, and Member, Editorial Board, ASSAY and Drug Development Technologies.

Previous articleFDA Lifts Clinical Hold on Proellex to Allow Escalating Low-Dose Safety and Efficacy Trial
Next articleScientists Find Link Between ARB Therapy and Cancer